Table 2.
Costs (US$) incurred by TB patients throughout treatment by methodological approach
| Cross-sectional approach 1a | Cross-sectional approach 2b | Longitudinal approach | ||||
|---|---|---|---|---|---|---|
| Treatment phase | Mean (95% CI) | Median (IQR) | Mean (95% CI) | Median (IQR) | Mean (95% CI) | Median (IQR) |
| Intensive phase | ||||||
| Direct medical | 24.39 (13.48–35.31) | 7.54 (3.23–18.76) | 4.04 (3.46–4.62) | 2.66 (1.46–4.56) | 12.40 (8.42–16.37) | 5.28 (2.74–10.97) |
| Direct non-medical | 6.46 (4.80–8.12) | 2.23 (0.00–6.15) | 4.41 (3.16–5.65) | 0.00 (0.00–4.50) | 5.20 (4.04–6.37) | 1.89 (0.25–5.40) |
| Indirect | 54.32 (45.94–62.71) | 32.74 (11.21–81.17) | 45.22 (39.03–51.40) | 18.05 (6.60–87.86) | 47.03 (40.96–53.10) | 30.62 (11.05–74.51) |
| Total | 85.18 (69.41–100.95) | 56.35 (21.72–108.34) | 53.67 (47.19–60.15) | 31.28 (12.51–98.87) | 64.63 (56.69–72.57) | 50.86 (19.98–92.65) |
| Continuationc phase | ||||||
| Direct medical | Not estimated | Not estimated | 8.06 (6.90–9.22) | 5.33 (2.92–9.12) | 7.92 (6.60–9.24) | 5.35 (3.18–9.23) |
| Direct non-medical | Not estimated | Not estimated | 8.68 (6.29–11.07) | 0.00 (0.00–9.00) | 3.36 (2.46–4.25) | 0.00 (0.00–3.43) |
| Indirect | Not estimated | Not estimated | 90.08 (77.79–102.37) | 36.11 (13.07–175.72) | 91.64 (79.65–103.63) | 36.87 (16.74–179.22) |
| Total | Not estimated | Not estimated | 106.83 (93.97–119.68) | 61.08 (25.02–197.73) | 102.92 (90.80–115.04) | 59.51 (26.57–184.53) |
| Intensive and continuation phase | Not estimated | Not estimated | 160.49 (141.16–179.82) | 91.63 (37.53–296.60) | 167.55 (149.65–185.45) | 119.42 (51.98–275.99) |
a
Patient costs extrapolated from the data provided in the first interview.
b
Patient costs are extrapolated from the data provided in the second interview.
c
Continuation phase estimates for the cross-sectional approach 1 are not displayed as the first interview collected intensive phase costs only.